BMY
Bristol-Myers Squibb Company
59.60$
-0.2%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.3% | 37.0% | 23.9% | 19.1% | 47.0% | 36.0% | 17.4% | 31.9% | 51.6% | 15.8% | 9.6% | 26.2% | 26.0% | |
| 22.2% | 21.5% | 21.3% | 21.3% | 21.8% | 15.2% | 9.0% | 8.2% | 8.3% | 7.8% | 5.2% | 4.6% | 6.5% | |
| 1.2% | 1.1% | 1.1% | 1.0% | 1.1% | 1.0% | 1.3% | 1.1% | 1.1% | 1.1% | 1.3% | 1.0% | 1.1% | |
| 0.7% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 2.7% | 7.4% | 1.7% | -19.4% | 14.4% | 10.3% | -16.7% | 0.1% | 25.0% | -13.2% | -26.1% | -4.8% | -4.5% | |
| 3.1% | 2.9% | 2.4% | 2.1% | 2.7% | 3.1% | 2.3% | 2.9% | 2.6% | 3.0% | 3.0% | 2.4% | 2.7% | |
| -3.7% | -11.7% | -165.3% | -10.8% | -1.8% | -1.6% | -4.5% | -3.9% | -13.9% | -11.7% | -1.1% | -12.4% | -10.0% | |
| 10.9% | 10.1% | 10.2% | 10.0% | 10.2% | 9.9% | 11.2% | 10.3% | 10.3% | 10.1% | 11.2% | 9.9% | 10.4% | |
| -36.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | -0.9% | – | – | |
| -0.1% | – | – | – | -22.3% | -3.3% | 3.3% | -4.8% | -1.8% | -37.9% | -1.6% | -10.4% | -13.2% | |
| -47.1% | 8.4% | 123.4% | -33.0% | -32.4% | -13.3% | -8.9% | -15.0% | -12.2% | -48.2% | -13.6% | -20.3% | -23.8% | |
| -7.8% | 34.4% | -18.4% | -24.9% | 13.4% | 19.9% | 4.7% | 14.1% | 25.5% | -44.1% | -5.5% | -6.6% | -7.9% | |
| 40.2% | 34.2% | 21.5% | 16.9% | 44.3% | 32.9% | 15.1% | 29.0% | 49.0% | 12.8% | 6.6% | 23.8% | 23.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.